Results 71 to 80 of about 4,177,143 (225)

Despite surge in orphan drug designations, approvals still lag [PDF]

, 2011
Monica Heger
openalex   +1 more source

Overexpression of LAG-3: a potential indicator of low immune function in tuberculosis

Frontiers in Cellular and Infection Microbiology
BackgroundTuberculosis (TB) persists as a global health challenge, with its treatment hampered by the side effects of long-term combination drug therapies and the growing issue of drug resistance.
Yun Pan, Zengxi Yao, Lifen Huang, Meina Xu, Ruichang Chen, Dengsheng Li, Xinyuan Wang, Jianchao Wu, Minran Li, Xujing Liang, Jiaxiong Tan, Jiaxiong Tan   +11 more
doaj   +1 more source

Gastroretentive Pulsatile Release Tablets of Lercanidipine HCl: Development, Statistical Optimization, and In Vitro and In Vivo Evaluation

The Scientific World Journal, 2014
The present study was aimed at the development of gastroretentive floating pulsatile release tablets (FPRTs) of lercanidipine HCl to enhance the bioavailability and treat early morning surge in blood pressure.
Gagganapalli Santhoshi Reddy, Usha Yogendra Nayak, Praful Balavant Deshpande, Srinivas Mutalik   +3 more
doaj   +1 more source

Drug lag bad: drug lack worse. [PDF]

British medical journal, 1980
openaire   +3 more sources

Long Lag Between Drug‐induced Parkinsonism and Idiopathic Parkinson's Disease in Idiopathic REM Sleep Behavior Disorder [PDF]

, 2017
Seyed‐Mohammad Fereshtehnejad, Benjamin Dawson, Amélie Pelletier, Jacques Montplaisir, Ronald B. Postuma   +4 more
openalex   +1 more source

Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug Administration [PDF]

, 2016
David S. Khoury, Deborah Cromer, Jörg J. Möhrle, James McCarthy, Miles P. Davenport   +4 more
openalex   +1 more source

Potential Impact of Accelerated Approval on the Drug Lags for Anticancer Drugs Between the United States and Japan

, 2020
Takashi Nagasawa, Atsushi Aruga
openalex   +2 more sources

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

Drug Design, Development and Therapy, 2015
Tetsuya Tanimoto Division of Social Communication System for Advanced Clinical Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan Abstract: The universal health care system in Japan is facing a historical turning point as a ...
Tanimoto T
doaj  

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

EMBO Molecular Medicine
Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells.
Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio, Maider Garnica, Miren Zuazo, Maria Jesus Garcia, Ana Bocanegra, Miriam Echaide, Colette Johnston, Carolyn J Edwards, James Legg, Andrew J Pierce, Hugo Arasanz, Gonzalo Fernandez-Hinojal, Ruth Vera, Karina Ausin, Enrique Santamaria, Joaquin Fernandez-Irigoyen, Grazyna Kochan, David Escors   +19 more
doaj   +1 more source

Outdoor particulate matter and risk of drug resistance for workers and farmers with pulmonary tuberculosis: a population-based time-series study in Suzhou, China

BMJ Open
Objectives The detrimental effects of particulate matter (PM) on human health have been widely corroborated. We aimed to examine the association between outdoor PM and the drug resistance risk among workers and farmers with pulmonary tuberculosis (PTB ...
Yun Li, Yu Wang, Xiaolong Zhang, Bilin Tao, Jun Jiang, Jianming Wang, Zhongqi Li, Ying Fu, Caiyan Cui, Feixian Wang   +9 more
doaj   +1 more source